Special Issue "Oncogenic Forms of BRAF as Cancer Driver Genes"

A special issue of Cancers (ISSN 2072-6694).

Deadline for manuscript submissions: 15 July 2019

Special Issue Editor

Guest Editor
Assoc. Prof. Dr. Trever G. Bivona

Division of Hematology/Oncology, Helen Diller Comprehensive Cancer Center, University of California, San Francisco, California, USA
Website | E-Mail
Interests: oncogenes; targeted therapy; drug resistance

Special Issue Information

Dear Colleagues,

BRAF mutations are among the most frequent oncogenic driver alterations in cancer and occur across different tumor histologies. There are 3 classes of BRAF mutations that promote oncogenesis: Class I, II, and III. Each class exhibits distinct properties, requires different therapeutic strategies, and is present in different tumor histologies. While effective, current targeted therapy approaches to treating BRAF-mutant cancers do not lead to cure or even chronic cancer control in most patients. Defining mechanisms of resistance to current RAF-pathway targeted therapies is of paramount importance to improve the duration of treatment response in patients and prolong long-term patient survival.

Several classes of RAF inhibitors, along with blockade of upstream, downstream, and parallel tumor-driving proteins are being explored for the treatment of BRAF-mutant tumors. An open question is which agents hold the most promise for clinical progress, and how we can maximize clinical benefit while minimizing treatment toxicities.

In this Special Issue, leading experts articulate the current understanding of BRAF-mutant cancer initiation, progression, and mechanisms of drug response and resistance. Research priorities and opportunities for progress against BRAF-mutant cancers are described, with the overall goal of transforming BRAF-mutant cancers from lethal into chronic conditions through precision medicine.

Assoc. Prof. Dr. Trever G. Bivona
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • BRAF
  • RAS
  • MEK
  • ERK
  • Oncogene
  • Targeted therapy
  • Drug resistance
  • Polytherapy

Published Papers

This special issue is now open for submission.
Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top